"Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe. The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 study in June 2018 with completion expected in mid-2019. The BTX 1204 Phase 1b atopic dermatitis patient study concluded in June 2018 and a Phase 2 study is due to commence in December 2018. The BTX 1308 Phase 1b psoriasis patient study commenced in September 2018."
I suspect something is around the corner ....
"Botanix pursues a rapid clinical development strategy aimed at...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.3¢ |
Change
0.013(3.91%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.0¢ | 31.5¢ | $1.047M | 3.220M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 158370 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 276320 | 7 |
View Market Depth
| Last trade - 15.59pm 25/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
